Deception in simplicity: Hereditary phospholamban mutations in dilated cardiomyopathy

Biochemistry and Cell Biology

Volumn 93, Issue 1, 2015, Pages 1-7

  Young, Howard S ^a   Ceholski, Delaine K ^a,b   Trieber, Catharine A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Heart failure; Phospholamban; Protein kinase A; Sarcoplasmic reticulum; SERCA

Indexed keywords

CARDIOLOGY; ENZYMES; HEART; PHOSPHORYLATION; PHYSIOLOGY; PROTEINS;

HEART FAILURE; PHOSPHOLAMBAN; PROTEIN KINASE A; SARCOPLASMIC RETICULUM; SERCA;

CALCIUM;

ADENOSINE TRIPHOSPHATASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; PHOSPHOLAMBAN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; CALCIUM; CALCIUM BINDING PROTEIN;

CALCIUM HOMEOSTASIS; CONGESTIVE CARDIOMYOPATHY; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART TRANSPLANTATION; HEREDITY; HUMAN; HYDROPHOBICITY; PROTEIN PHOSPHORYLATION; REVIEW; SARCOPLASMIC RETICULUM; WILD TYPE; GENETICS; METABOLISM; MUTATION; PHOSPHORYLATION;

CALCIUM; CALCIUM-BINDING PROTEINS; CARDIOMYOPATHY, DILATED; HUMANS; MUTATION; PHOSPHORYLATION; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES;

EID: 84921941958     PISSN: 08298211     EISSN: 12086002     Source Type: Journal    
DOI: 10.1139/bcb-2014-0080     Document Type: Review

References (35)

1. Abecasis G.R. Altshuler D. Auton A. Brooks L.D. Durbin R.M. Gibbs R.A. et al. The 1000 Genomes Project Consortium 2010. A map of human genome variation from population-scale sequencing. Nature (Lond.), 467: 1061-1073. 10.1038/nature09534. 20981092.
2. Ablorh, N.-A.D., Dong, X., James, Z.M., Xiong, Q., Zhang, J., Thomas, D.D., and Karim, C.B. 2014. Synthetic Phosphopeptides Enable Quantitation of the Content and Function of Phospholamban's four Phosphorylation States in Cardiac Muscle. J. Biol. Chem. In press. 10.1074/jbc.M114.556621. 25190804.
3. Catalucci D. Latronico M.V.G. Ceci M. Rusconi F. Young H.S. Gallo P. Santonastasi M. Bellacosa A. Brown J.H. Condorelli G. 2009. Akt increases sarcoplasmic reticulum Ca2+ cycling by direct phosphorylation of phospholamban at Thr17. J. Biol. Chem. 284: 28180-28187. 10.1074/jbc.M109.036566. 19696029.
4. Ceholski D.K. Trieber C.A. Holmes C.F. Young H.S. 2012 a. Lethal, hereditary mutants of phospholamban elude phosphorylation by protein kinase a. J. Biol. Chem. 287: 26596-26605. 10.1074/jbc.M112.382713. 22707725.
5. Ceholski D.K. Trieber C.A. Young H.S. 2012 b. Hydrophobic imbalance in the cytoplasmic domain of phospholamban is a determinant for lethal dilated cardiomyopathy. J. Biol. Chem. 287: 16521-16529. 10.1074/jbc.M112.360859. 22427649.
6. Chothia C. 1976. The nature of the accessible and buried surfaces in proteins. J. Mol. Biol. 105: 1-12. 10.1016/0022-2836(76)90191-1. 994183.
7. Dellefave L. McNally E.M. 2010. The genetics of dilated cardiomyopathy. Curr. Opin. Cardiol. 25: 198-204. 10.1097/HCO.0b013e328337ba52. 20186049.
8. DeWitt M.M. MacLeod H.M. Soliven B. McNally E.M. 2006. Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy. J. Am. Coll. Cardiol. 48: 1396-1398. 10.1016/j.jacc.2006.07.016. 17010801.
9. Ha K.N. Masterson L.R. Hou Z. Verardi R. Walsh N. Veglia G. Robia S.L. 2011 Lethal Arg9Cys phospholamban mutation hinders Ca2+-ATPase regulation and phosphorylation by protein kinase A. Proc. Natl. Acad. Sci. U.S.A. 108: 2735-2740. 10.1073/pnas.1013987108. 21282613.
10. Haghighi K. Kolokathis F. Pater L. Lynch R.A. Asahi M. Gramolini A.O. Fan G.C. Tsiapras D. Hahn H.S. Adamopoulos S. Liggett S.B. Dorn G.W. 2nd MacLennan D.H. Kremastinos D.T. Kranias E.G. 2003. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J. Clin. Invest. 111: 869-876. 10.1172/JCI200317892. 12639993.
11. Haghighi K. Kolokathis F. Gramolini A.O. Waggoner J.R. Pater L. Lynch R.A. Fan G.C. Tsiapras D. Parekh R.R. Dorn G.W. 2nd MacLennan D.H. Kremastinos D.T. Kranias E.G. 2006. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc. Natl. Acad. Sci. U.S.A. 103: 1388-1393. 10.1073/pnas.0510519103. 16432188.
12. Haghighi K. Chen G. Sato Y. Fan G.C. He S. Kolokathis F. Pater L. Paraskevaidis I. Jones W.K. Dorn G.W. 2nd Kremastinos D.T. Kranias E.G. 2008. A human phospholamban promoter polymorphism in dilated cardiomyopathy alters transcriptional regulation by glucocorticoids. Hum. Mutat. 29: 640-647. 10.1002/humu.20692. 18241046.
13. Hasenfuss G. Reinecke H. Studer R. Meyer M. Pieske B. Holtz J. Holubarsch C. Posival H. Just H. Drexler H. 1994. Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium. Circ. Res. 75: 434-442. 10.1161/01.RES.75.3.434. 8062417.
14. Hershberger R.E. Hedges D.J. Morales A. 2013. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat. Rev. Cardiol. 10: 531-547. 10.1038/nrcardio.2013.105. 23900355.
15. Kirchberger M. Tada M. Katz A. 1975. Phospholamban: a regulatory protein of the cardiac sarcoplasmic reticulum. Recent Adv. Stud. Cardiac Struct. Metab. 5: 103-115. 127351.
16. Landstrom A.P. Adekola B.A. Bos J.M. Ommen S.R. Ackerman M.J. 2011. PLN-encoded phospholamban mutation in a large cohort of hypertrophic cardiomyopathy cases: summary of the literature and implications for genetic testing. Am. Heart J. 161: 165-171. 10.1016/j.ahj.2010.08.001. 21167350.
17. MacLennan D. Kranias E. 2003. Phospholamban: a crucial regulator of cardiac contractility. Nat. Rev. Mol. Cell Biol. 4: 566-577. 10.1038/nrm1151. 12838339.
18. Masterson L.R. Shi L. Metcalfe E. Gao J. Taylor S.S. Veglia G. 2011. Dynamically committed, uncommitted, and quenched states encoded in protein kinase A revealed by NMR spectroscopy. Proc. Natl. Acad. Sci. U.S.A. 108: 6969-6974. 10.1073/pnas.1102701108. 21471451.
19. Mattiazzi A. Mundiña-Weilenmann C. Guoxiang C. Vittone L. Kranias E. 2005. Role of phospholamban phosphorylation on Thr17 in cardiac physiological and pathological conditions. Cardiovasc. Res. 68: 366-375. 10.1016/j.cardiores.2005.08.010. 16226237.
20. Medeiros A. Biagi D.G. Sobreira T.J.P. de Oliveira P.S.L. Negrão C.E. Mansur A.J. Krieger J.E. Brum P.C. Pereira A.C. 2011. Mutations in the human phospholamban gene in patients with heart failure. Am. Heart J. 162: 1088-1095. 10.1016/j.ahj.2011.07.028. 22137083.
21. Mestroni L. Taylor M.R. 2013. Genetics and genetic testing of dilated cardiomyopathy: a new perspective. Discov. Med. 15: 43-49. 23375013.
22. Meyer M. Schillinger W. Pieske B. Holubarsch C. Heilmann C. Posival H. Kuwajima G. Mikoshiba K. Just H. Hasenfuss G. 1995. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation, 92: 778-784. 10.1161/01.CIR.92.4.778. 7641356.
23. Minamisawa S. Sato Y. Tatsuguchi Y. Fujino T. Imamura S. Uetsuka Y. Nakazawa M. Matsuoka R. 2003. Mutation of the phospholamban promoter associated with hypertrophic cardiomyopathy. Biochem. Biophys. Res. Commun. 304: 1-4. 10.1016/S0006-291X(03)00526-6. 12705874.
24. Moore M.J. Adams J.A. Taylor S.S. 2003. Structural basis for peptide binding in protein kinase A. Role of glutamic acid 203 and tyrosine 204 in the peptide-positioning loop. J. Biol. Chem. 278: 10613-10618. 10.1074/jbc.M210807200. 12499371.
25. Neuberger G. Schneider G. Eisenhaber F. 2007. pkaPS: prediction of protein kinase A phosphorylation sites with the simplified kinase-substrate binding model. Biol. Direct, 2: 1. 10.1186/1745-6150-2-1. 17222345.
26. Schmitt J.P. Kamisago M. Asahi M. Li G.H. Ahmad F. Mende U. Kranias E.G. MacLennan D.H. Seidman J.G. Seidman C.E. 2003. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science, 299: 1410-1413. 10.1126/science.1081578. 12610310.
27. Schmitt J.P. Ahmad F. Lorenz K. Hein L. Schulz S. Asahi M. Maclennan D.H. Seidman C.E. Seidman J.G. Lohse M.J. 2009. Alterations of phospholamban function can exhibit cardiotoxic effects independent of excessive sarcoplasmic reticulum Ca2+-ATPase inhibition. Circulation, 119: 436-444. 10.1161/CIRCULATIONAHA.108.783506. 19139388.
28. Simmerman H.K.B. Collins J.H. Theibert J.L. Wegener A.D. Jones L.R. 1986. Sequence Analysis of Phospholamban: Identification of Phosphorylation Sites and Two Major Structural Domains. J. Biol. Chem. 261: 13333-13341. 3759968.
29. Traaseth N.J. Ha K.N. Verardi R. Shi L. Buffy J.J. Masterson L.R. Veglia G. 2008. Structural and dynamic basis of phospholamban and sarcolipin inhibition of Ca(2+)-ATPase. Biochemistry, 47: 3-13. 10.1021/bi701668v. 18081313.
30. Verardi R. Shi L. Traaseth N.J. Walsh N. Veglia G. 2011. Structural topology of phospholamban pentamer in lipid bilayers by a hybrid solution and solid-state NMR method. Proc. Natl. Acad. Sci. U.S.A. 108: 9101-9106. 10.1073/pnas.1016535108. 21576492.
31. Yu X. Lorigan G.A. 2013. Probing the interaction of Arg9Cys mutated phospholamban with phospholipid bilayers by solid-state NMR spectroscopy. Biochim. Biophys. Acta, 1828: 2444-2449. 10.1016/j.bbamem.2013.07.003. 23850636.
32. Yu X. Lorigan G.A. 2014. Secondary structure, backbone dynamics, and structural topology of phospholamban and its phosphorylated and Arg9Cys-mutated forms in phospholipid bilayers utilizing 13C and 15N solid-state NMR spectroscopy. J. Phys. Chem. B, 118: 2124-2133. 10.1021/jp500316s. 24511878.
33. Zhao G. London E. 2006. An amino acid "transmembrane tendency" scale that approaches the theoretical limit to accuracy for prediction of transmembrane helices: relationship to biological hydrophobicity. Protein Sci. 15: 1987-2001.
34. Zhao W. Yuan Q. Qian J. Waggoner J.R. Pathak A. Chu G. Mitton B. Sun X. Jin J. Braz J.C. Hahn H.S. Marreez Y. Syed F. Pollesello P. Annila A. Wang H.S. Schultz Jel, J. Molkentin J.D. Liggett S.B. Dorn G.W. 2nd Kranias E.G. 2006. The presence of Lys27 instead of Asn27 in human phospholamban promotes sarcoplasmic reticulum Ca2+-ATPase superinhibition and cardiac remodeling. Circulation, 113: 995-1004. 10.1161/CIRCULATIONAHA.105.583351. 16476846.
35. Zvaritch E. Backx P.H. Jirik F. Kimura Y. de Leon S. Schmidt A.G. Hoit B.D. Lester J.W. Kranias E.G. MacLennan D.H. 2000. The transgenic expression of highly inhibitory monomeric forms of phospholamban in mouse heart impairs cardiac contractility. J. Biol. Chem. 275: 14985-14991. 10.1074/jbc.275.20.14985. 10809743.